Showing results (1-10 of 38) with videos related to
Sort By:
Pageof 4
Human Vaccines & Immunotherapeutics|April 9, 2013
Cancer vaccines: identification of biomarkers predictive of clinical efficacyRichard HarropFrontiers in Bioscience : a Journal and Virtual Library|September 9, 2005
Viral vectors for cancer immunotherapyRichard Harrop, Miles W CarrollCancer Immunology, Immunotherapy : CII|October 21, 2016
5T4 oncofoetal antigen: an attractive target for immune intervention in cancerPeter L Stern, Richard HarropTherapeutic Advances in Vaccines and Immunotherapy|February 6, 2019
Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigenRichard Harrop, Eric O'Neill, Peter L SternAdvanced Drug Delivery Reviews|October 13, 2006
Recombinant viral vectors: cancer vaccinesRichard Harrop, Justin John, Miles W CarrollInternational Immunology|June 24, 2008
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4William H Shingler, Priscilla Chikoti, Susan M Kingsman, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patientsRichard Harrop, William Shingler, Michelle Kelleher, et al.Methods in Molecular Biology (Clifton, N.J.)|April 29, 2004
Monitoring of human immunological responses to vaccinia virusRichard Harrop, Matthew G Ryan, Hana Golding, et al.Cancer Immunology, Immunotherapy : CII|July 24, 2013
Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trialRichard Harrop, Franklin Chu, Nashat Gabrail, et al.Immunology|April 25, 2006
Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4Irina Redchenko, Richard Harrop, Matthew G Ryan, et al.Pageof 4